Beyond ocrelizumab in primary progressive multiple sclerosis

被引：0

作者：

Williams, Thomas ^{[1
]}

Chataway, Jeremy ^{[1
,2
]}

机构：

[1] UCL, Fac Brain Sci, UCL Queen Sq Inst Neurol, Queen Sq Multiple Sclerosis Ctr,Dept Neuroinflamm, London, England

[2] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England

来源：

NATURE REVIEWS NEUROLOGY | 2022年 / 18卷 / 11期

基金：

英国医学研究理事会;

关键词：

THERAPY;

D O I：

10.1038/s41582-022-00724-8

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Currently, the anti-CD20 monoclonal antibody ocrelizumab is the only approved treatment for primary progressive multiple sclerosis (PPMS). However, a new study suggests that other immunomodulatory disease-modifying therapies that are often used to treat relapsing forms of multiple sclerosis could be effective in people with PPMS who have evidence of active inflammatory disease.

引用

页码：641 / 642

页数：2

共 50 条

[31] Real world experience with ocrelizumab in patients with primary progressive multiple sclerosis
Lopez Ruiz, R.
Dotor Garcia-Soto, J.
Hiraldo, J. D. G.
Ruiz-Pena, J. L.
Paramo Camino, M. D.
Ruiz De Arcos, M.
Navarro Mascarell, G.
Eichau Madueno, S.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 301 - 302
[32] SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Di Maio, D.
Liu, C.
Marcelli, G.
Alvarez, Sanchez J.
Overell, J.
[J]. VALUE IN HEALTH, 2020, 23 : S632 - S633
[33] Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
Daniels, K.
van der Nat, P. B.
Frequin, S. T. F. M.
van der Wees, P. J.
Biesma, D. H.
Hoogervorst, E. L. J.
van de Garde, E. M. W.
[J]. MULTIPLE SCLEROSIS INTERNATIONAL, 2020, 2020
[34] Effect of Ocrelizumab on Thalamic Atrophy in Patients with Relapsing and Primary Progressive Multiple Sclerosis
Arnold, Douglas L.
Sprenger, Till
Bar-Or, Amit
Wolinsky, Jerry S.
Kappos, Ludwig
Kolind, Shannon
Manfrini, Marianna
Magon, Stefano
van Beek, Johan
Koendgen, Harold
Bernasconi, Corrado
Gaetano, Laura
Traboulsee, Anthony
[J]. NEUROLOGY, 2020, 94 (15)
[35] Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
Zanghi, Aurora
Ferraro, Diana
Callari, Graziella
Valentino, Paola
Granella, Franco
Patti, Francesco
Lus, Giacomo
Bonavita, Simona
Moretti, Maria Claudia
Avolio, Carlo
D'Amico, Emanuele
[J]. CURRENT NEUROPHARMACOLOGY, 2024, 22 (02) : 339 - 345
[36] Primary progressive multiple sclerosis to be treated with ocrelizumab: a mistaken case of cobalamin deficiency
Feldman, Sydney
Aljarallah, Salman
Saidha, Shiv
[J]. BMJ CASE REPORTS, 2019, 12 (05)
[37] Monoclonal antibody ocrelizumab for primary-progressive multiple sclerosis in adults: a systematic review
Klabukova, D.
Davydovskaya, M.
Ermolaeva, T.
Holownia-Voloskova, M.
Polyakova, K.
Fisun, A.
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S32 - S32
[38] Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis
Kappos, L.
Giovannoni, G.
de Seze, J.
Montalban, X.
Wolinsky, J.
Belachew, S.
Deol-Bhullar, G.
Han, J.
Julian, L.
Hauser, S. L.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 44 - 44
[39] Ocrelizumab in people with primary progressive multiple sclerosis: A real-world multicentric study
Skoric, Magdalena Krbot
Kes, Vanja Basic
Grbic, Nevena
Lazibat, Ines
Pavelin, Sanda
Zubonja, Tea Mirosevic
Komso, Milica
Piskac, Spomenka Kidemet
Abicic, Ana
Piskac, Dominik
Adamec, Ivan
Barun, Barbara
Gabelic, Tereza
Habek, Mario
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89
[40] Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study
de Antonio, Luis A. Rodriguez
Cuberta-Gonzalez, Ines
Garcia-Castanon, Inmaculada
Oreja-Guevara, Celia
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 69

← 1 2 3 4 5 →